NCT06696846 CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia
| NCT ID | NCT06696846 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Condition | Relapsed/Refractory T-cell Lymphoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2024-12-01 |
| Primary Completion | 2027-11-30 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
CD70 is a promising target for immunotherapy because it is overexpressed in T-cell lymphoma (TCL) and acute myeloid leukemia (AML) tumor cells but is found in deficient levels in normal tissues and hematopoietic stem cells. This study aims to evaluate the safety and efficacy of CD70-targeted CAR-NK (CD70-CAR-NK) cells in patients with relapsed and refractory TCL and AML.
Eligibility Criteria
Inclusion Criteria: According to the WHO disease classification, patients with relapsed/refractory T - lymphoma and acute myeloid leukemia: 1. Voluntarily participate in this study and sign the informed consent form; 2. Aged between 18-75 years old, both male and female are eligible; 3. Relapsed/refractory T cell lymphoma is defined as: relapsed/refractory after having received at least two or more lines of previous treatment (patients with anaplastic large -cell lymphoma must have been exposed and resistant to Brentuximab vedotin). The celluar subtypes of T-cell lymphoma include: angioimmunoblastic T-cell lymphoma; peripheral T - cell lymphoma not otherwise specified; ALK-negative anaplastic large - cell lymphoma; Relapsed/refractory AML is defined as: leukemia cells reappear in the peripheral blood after complete remission or the blasts in the bone marrow ≥ 5% or the extramedullary leukemia infiltration outside. Or newly diagnosed cases did not achieve a CR after two courses of stand